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Albeit a very large number of experiments have assessed the impact of various substrates on liver regeneration after partial
hepatectomy, a limited number of clinical studies have evaluated artiﬁcial nutrition in liver resection patients. This is a peculiar
topic because many patients do not need artiﬁcial nutrition, while several patients need it because of malnutrition and/or
prolonged inability to feeding caused by complications. The optimal nutritional regimen to support liver regeneration, within
otherpostoperativeproblemsorcomplications,isnotyetexactlydeﬁned.Thisshortreviewaddressesrelevantaspectsandpotential
developments in the issue of postoperative parenteral nutrition after liver resection.
1.Introduction
Although there has been a plethora of animal studies on
factors and nutritional substrates supporting or inhibiting
liverregenerationafterliverresection(LR),alimitednumber
of human studies has addressed parenteral or enteral nutri-
tion in LR. This is a peculiar topic. Indeed, most surgeons
do not give particular value to substrate infusion after LR,
because most patients can resume an oral diet within the
3rd or the 4th postoperative day, so that starvation does not
become an issue. Therefore, it is diﬃcult to ﬁnd evidence-
based information or guidelines on this topic.
On the other hand, major LR, compared to other ab-
dominal operations, is characterized by a speciﬁc need for
substrate for liver regeneration, and in extreme cases also
by competition for substrate to simultaneously support
acute phase response, liver regeneration, and host defence
if postoperative sepsis occurs [1]. Nutritional support may
become an issue not only when the resumption of feeding is
prevented by complications and prolonged illness, but also
soon postoperatively in malnourished patients with a high
risk of complications.
2.Randomized Studies
Among the clinical studies which have addressed artiﬁcial
nutrition in LR in previous decades, there are also ran-
domized protocols comparing parenteral to enteral nutrition
after LR, or even preoperatively [2–7]. The results are
relevant, and, in particular, one of them clearly shows that
artiﬁcial nutrition improves the outcome of hepatectomy
in cirrhotic patients [2]. However again, these studies
are not suﬃcient to establish realistic indications. Firstly,
preoperative artiﬁcial nutrition does not comply with the
current practice of patient management and hospitaliza-
tion. Secondly, as already mentioned, after surgery most
patients rapidly restart oral feeding without a clear need
for artiﬁcial nutrition. Thirdly, when artiﬁcial nutrition is
indicated because of prolonged inability to feeding, there
are often various combinations of malnutrition, acute liver
dysfunction, and sepsis whose complex management largely
overcomes that of routinely recovering LR patients. Up until
now, there are no guidelines speciﬁcally considering the
need to support liver regeneration within other problems
and complications, and nutritional prescriptions are still2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
empiricallytailored.Althoughourexperienceismostlybased
on parenteral nutrition, even an evidence-based choice of
enteral or parenteral nutrition remains an unsolved issue.
The reasonable option is to take advantage of both, when
artiﬁcial nutrition is indicated, as the former maintains
bowel integrity and gut wall barrier function, while the latter
allows the obtainment of full-regimen support and ﬂuid-
electrolyte balance, which may not always be attainable by
enteral nutrition alone.
3. Patients with Malnutrition
Important malnutrition [8]m a yb ear e a s o nt od e l a ym a j o r
surgery for a few weeks if a preoperative improvement in
nutritional state is achievable. For instance, malnutrition
is sometimes associated with severe obstructive jaundice in
patients with hilar cholangiocarcinoma (Klatskin tumor). In
these cases the postponement of major hepatectomy may
simultaneously be dictated by the need for biliary drainage
to treat jaundice, for portal embolization to hypertrophy
future remnant liver, and for the improvement of nutritional
state [9]. Furthermore, given the high risk of complications
and prolonged illness, full-regimen parenteral nutrition is
started soon postoperatively. Similar considerations apply
to cirrhotic patients after major hepatectomy, in whom
liver regeneration and recovery may be more dependent on
appropriate nutritional support [10].
4. Choice of Substrates
We perform at present about 150 LR per year, and it has
long been our standard to administer to all patients from
the 1st p.o. day a dose of at least 2.0–2.5g/kg/day dextrose
and 0.8–1.0g/kg/day amino acids (35 to 50% branched chain
amino acids) [9, 11]. This is to moderate the catabolic drive
(glycogenolysis, and proteolysis for gluconeogenesis) and to
providesomesupportforliverregeneration,asglucosealone,
unless associated with other substrates, does not seem to
support hepatic regeneration [12–14]. Intravenous infusions
are withdrawn with the resumption of oral feeding, in
general within the 3rd or 4th postoperative day.
If a complication prevents feeding, the regimen is aug-
mented to full-dose parenteral nutrition providing 30 to
35Kcal/kg/day (about 50% dextrose and 50% fat, preferen-
tially using a mixed fat emulsion with 50% medium chain
and 50% long chain triglycerides) and about 1.5g/kg/day
aminoacids(35to50%branchedchainaminoacids) [9,11].
A similarly robust support is started soon postoperatively in
patients with malnutrition and/or an expected greater risk
of complications. This regimen is similar to independently
developedregimensadoptedforLRinlivercirrhosis,inother
patients after major LR and in living donors for liver trans-
plantation [10, 15–17]. Apart from the favourable properties
of medium chain triglycerides [10, 18], we simply consider
theiruseasameansofdistributingthecalorieloadoverthree
diﬀerent substrates (dextrose, long chain, and medium chain
triglycerides) therefore avoiding problems associated with
high doses of single substrates (diﬃcult glycemic control,
excessive load of linoleic acid, etc.). The supply of high doses
of branched chain amino acids (BCAAs), within the total
amino acid dose, is to take advantage of their moderate
anticatabolic and proanabolic eﬀect, and of other favourable
properties [10, 19, 20]; there is also long-lasting consensus
on their eﬀects in experimental studies on liver regeneration
[13, 14, 21]. Of note, BCAA or BCAA-enriched amino acid
solutions are not particularly expensive in Italy.
Appropriate amounts of electrolytes, vitamins, and trace
elements are obviously needed. Within micronutrients,
particularattentionisgiventophosphatesupply.Itisunclear
whether early severe hypophosphatemia after LR depends
on increased metabolic consumption, urinary loss, or other
mechanisms [22–24]. Anyhow it seems to predict a higher
risk of complications, and there is some evidence that
phosphate replacement is associated with better outcome,
also in living donors for liver transplantation [22, 25]; this
needs to be conﬁrmed in further studies.
5. Complications
The most common complications after LR are transient
liver insuﬃciency and sepsis. Transient liver insuﬃciency in
itself might not be a reason to modify nutritional support.
However, the presence of encephalopathy may involve the
reduction or interruption of fat infusion, which can worsen
this symptom [18, 26]. A relatively high total amino acid
dose (1.0–1.5g/kg/day) in the presence of liver insuﬃ-
ciency should not be of concern if this include a large
percentage of BCAAs. BCAAs do not represent additional
burden for the liver because they are primarily metabolized
in other tissues; thereafter, the liver advantageously uses
their metabolites [19, 20]. High BCAA doses maintain a
high plasma BCAA/aromatic amino acid ratio and better
control this component of hepatic encephalopathy, maintain
some anticatabolic and proanabolic drive, improve energy
metabolism, and have other properties which can also
include a contribution to reducing ammonia levels [27].
Sometimes in severe encephalopathy there is a need to
infuse only BCAAs, interrupting the infusion of other amino
acids [28]. Simultaneous dextrose infusion may contribute
to increase the BCAA/aromatic amino acid ratio by reducing
the endogenous aromatic amino acid load from protein
catabolism, while cleaning of the bowel and/or manipulation
of its microbial ﬂora reduce endogenous ammonia produc-
tion.
Unfortunately these supportive measures cannot be of
major help when very severe hepatic insuﬃciency occurs
from too small residual liver or other major complications
aﬀecting its function. Despite occasional reports on major
beneﬁts of nutrition [29], one cannot rely on nutrition to
postoperatively enhance function of a small residual liver.
Theissuemustberesolvedinadvance,bypreoperativeportal
embolization to hypertrophy future remnant liver, or by
excluding the patient from resection. In our policy future
remnant liver should at least be 25–30% in normal adults
and 45–50% in cirrhotic patients, with an intermediate
percentage in patients with steatosis or steatohepatitis fromJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
chemotherapy before LR for metastases, or in patients with
cholestaticliver.Hence,realisticallyparenteralnutritionafter
LR can only represent a helpful supportive tool when tran-
sient liver insuﬃciency develops in spite of all precautions.
Liver resection predisposes to sepsis by a variety of
mechanisms, including the removal of liver cells involved
in host defence [9], and there is well-known synergism of
sepsis and liver dysfunction in determining a poor outcome
[9, 30, 31]. Of course, treatment of sepsis is the main target,
however,nutritionalsupportalsohasarelevantrole.Amajor
surgical procedure which is often associated with septic
complications is LR for hilar cholangiocarcinoma. When the
patients present with severe obstructive jaundice, there is a
need for preoperative biliary drainage which predisposes to
microbial contamination of the biliary tree, with a greater
risk of sepsis after surgery in a contaminated ﬁeld. Because
surgery often consists of a major or extended hepatectomy,
sepsis is often overimposed on transient liver insuﬃciency
[9].
When sepsis develops, the treatment should not diverge
much from the common guidelines for sepsis. These include
the tailoring of dextrose load according to glucose intol-
erance, the supply of fat emulsions not containing large
amounts of the omega-6 polyunsaturated linoleic acid to
avoid excessive ampliﬁcation of the inﬂammatory response,
and a daily dose of 1.5–2.0g/kg amino acids (35 to 50%
BCAAs). We believe that the use of high-dose insulin to
allow large dextrose loads is unsafe in normal surgical wards,
because of the risk of hypoglycemic accidents. Reduction
of the linoleic acid dose is permitted by using mixed
emulsions with 50% long chain and 50% medium chain
triglycerides, or olive oil-based emulsions, while additional
ﬁsh oil emulsions may provide an integration of omega-3
polyunsaturated fatty acids. There are also newly available
mixed emulsions containing all these components together
(long chain, medium chain triglycerides, and ﬁsh oil, with or
withoutolive oil) althoughpublished experience ontheir use
inLRislacking.Thetotalcaloriedose(dextrose+fat)should
be about 30 to 35kcal/kg/day. With regard to the combined
use of enteral nutrition (whenever feasible) in sepsis, this
seems to enhance gut wall barrier function and moderate
inﬂammatory response, while in severe liver insuﬃciency
andencephalopathyenteralnutrition might not be desirable.
At any rate, the important concept to emphasize is that,
once infection appears, the clinical course could rapidly go
downhill. Therefore, parenteral nutrition should be given to
patientsatriskimmediatelyafterLR.Inaddition,itshouldbe
continuedevenwhenthepatientshaveresumedoralfeeding,
which may not be suﬃcient to cover metabolic demands in
the initial period. The patients at greater risk are those with
liver cirrhosis, major hepatectomy, and concomitant biliary
tract infection or bacterial colonization.
6. Biochemical Measurements
There is a well-known series of biochemical measurements
which are commonly performed after LR, or in complicated
cases undergoing parenteral nutrition, and do not deserve
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Figure 1: Patients on parenteral nutrition after LR. Within
the main group of measurements (encircled), there is general
reduction in plasma cholesterol compared to preoperative value,
with low-normal triglycerides. A: measurement with the lowest
cholesterol and highest triglyceride levels, without fat infusion,
signalling the transition of a septic patient to preterminal illness
and shock. B: measurements with less severe hypertriglyceridemia
signalling transient but reversible worsening of septic illness in two
patients undergoing fat infusion. C: measurements with increased
cholesterol associated with development of cholestasis in another
patient.
particularnotes.Converselythedosageofplasmacholesterol,
triglycerides,cholinesterase,andbloodureanitrogendeserve
some comment. Transient hypocholesterolemia is a normal
consequence of surgery, and after LR is mainly related to
extent of liver resection, severity of acute-phase response,
hemodilution from blood loss, and liver dysfunction, if
present. Normally hypocholesterolemia progressively recov-
ers. Persistent, or persistently severe hypocholesterolemia
after LR has a diﬀerent relevance, because it is related to
sepsis or to a synergic combination of sepsis and liver
insuﬃciency and very poor prognosis [32, 33]. Of note,
cholestasis, if present, moderates the degree of hypoc-
holesterolemia. These concepts implicate that persistent
hypocholesterolemia after LR has very little to do with
nutritional state, or with the infusion of fat. Fat emulsions
containonlyanirrelevant amount ofcholesterol.Conversely,
serum triglyceride levels usefully reﬂect the plasma clearance
of the infused fat. In sepsis the observation of normal or
low triglycerides does not have particular relevance, while
hypertriglyceridemia may reﬂect both the worsening of the
septic state and/or excessive fat load compared to clearance
[33, 34]. Indeed, although in sepsis fat is a preferential
substrate,inextremesepticillnessimpairedfatclearancemay
develop, therefore, determining moderate-to-severe hyper-
triglyceridemia (Figure 1). The dosage of plasma butyryl-
cholinesterase (CHE) is another useful adjunct because
decreasing CHE, like decreasing cholesterol, may reﬂect both
severity of acute phase response (sepsis) and severity of liver
dysfunction [35], with a risk of poor outcome. The practical
implication is the need for the aggressive resolution of a
septic focus, if present. Of note, the transfusion of fresh4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
frozen plasma or blood can increase CHE independently of
the underlying condition. As in the case of cholesterol, the
anecdotal relationship between CHE and nutritional state
is lost in critical illness although CHE seems to maintain
some direct relationship with the amino acid dose [35].
Increased blood urea nitrogen with normal creatinine may
commonly reﬂect protein hypercatabolism (especially in
sepsis), bleeding in the gastrointestinal tract, and sometimes
renal dysfunction from hypovolemia. It may also reﬂect
increased exogenous amino acid dose; however, it is often
gratifying to observe a decrease in blood urea nitrogen,
for any given creatinine and amino acid dose, related to
increasing doses of dextrose and fat, therefore reﬂecting a
better use of amino acids for protein synthesis.
7. New and RelatedInterventions
Among other aspects, recent information is addressing the
beneﬁts of perioperative dextrose and insulin administra-
tion in LR (starting already preoperatively) to maintain
hepatic glycogen stores; this seems to be associated with
better recovery of liver function and also protection from
ischemia/reperfusion injury [29, 36]. With regard to the
newly developed mixed fat emulsions with long chain,
medium chain triglycerides and ﬁsh oil, with or without
olive oil, it is very likely that LR patients can beneﬁt
from each of these fat components while avoiding potential
harm from high doses of single fat substrates. As already
mentioned, evidence-based information is lacking, and
evaluation of these mixed emulsions in the clinical setting
has greater priority over ordinary comparisons between
the previously available and simpler emulsions. Finally,
with regard to BCAAs, other interesting aspects which
deserve mention, although beyond the topic of this short
review, are the reported beneﬁts of preoperative oral BCAA
supplementation on the early response to LR [37], and the
better long term outcome associated with protracted oral
supplementation with BCAAs and carbohydrates, after LR
for cancer in cirrhotic patients [38].
In conclusion, parenteral nutrition in LR patients still
remains a poorly deﬁned ﬁeld. Firstly because most LR
patients only needsome short-termandlight parenteral sup-
port, while a formal parenteral nutrition regimen is required
in peculiar or complicated cases. Secondly because, despite
a plenitude of animal experiments, there is no evidence-
based data for the optimal combination of substrates to
support liver regeneration and liver function in the clinical
setting. This diﬀers from the experimental setting. Indeed,
the ability of the liver to regenerate after resection in humans
depends on many factors such as the remnant liver size, the
quality of the liver remnant, the damage to the liver remnant
during and after surgery, concomitant sepsis, and bile duct
obstruction or damage. Hence, it is quite diﬃcult to conﬁrm
animal experimental ﬁndings in patients unless uniﬁed
groups of patients are included in the studies. Therefore,
guidelines remain relatively empirical, and the ﬁeld remains
open to future and more speciﬁc investigations.
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